OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancerRecruitment on track in OCTOPOD-IV, a Phase 1/2a ...
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases. In some patients, the disease returns or progresses within six months of the ...
On April 11, Corcept Therapeutics Inc. (NASDAQ:CORT) released the overall survival results from its Phase 3 ROSELLA study ...
BELLA (NCT06906341) has completed enrollment testing triplet strategies such as adding bevacizumab and expanding evaluation ...
The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...
When a cancer diagnosis is made, conversations about fertility preservation often need to happen quickly. In this discussion, ...
Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ovarian cancer diagnosis this year. Subscribe to our newsletter for the ...
LITTLE ROCK, Ark. — One Arkansas woman who was diagnosed with a rare and stubborn form of ovarian cancer recently received a life-changing opportunity to benefit from a clinical trial at the UAMS ...
The National Ovarian Cancer Coalition (NOCC) delivers free meals to ovarian cancer patients, easing treatment burdens and ...
DANIELLA Capitas Webster was diagnosed with cancer at just 22, after her stomach became so bloated she looked “pregnant”. She ...
Low-grade serous ovarian cancer (LGSOC) is a rare type of ovarian cancer that's often slow-growing and hard to detect early and treat. It can start in your: Ovaries, where your pregnancy hormones and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results